Comments*

 
  • Cell & Molecular Biology

  • Events 

    June 19 - 20, 2013

    Progressive Multifocal Leukoencephalopathy

    Conference Planning Committee: Claudio Carini (Pfizer Inc.), Teresa Compton (Biogen Idec (Conference Chair)), Marion Kasaian (Pfizer Inc.), Theodora Salcedo (Bristol-Myers Squibb Company), Anne Vogt (F. Hoffmann-La Roche Ltd)
    Scientific Advisory Board: Leonard Calabrese (Cleveland Clinic), Paola Cinque (Hospital San Raffaele), David Clifford (Washington University School of Medicine), Robert Garcea (University of Colorado at Boulder), Eugene Major (National Institute of Neurological Disorders and Stroke), Kenneth Tyler (University of Colorado Anschutz Medical Campus), Thomas Weber (University of Hamburg)

    New basic science and clinical findings relevant to the pathogenesis, mitigation, cure, and risk stratification of Progressive Multifocal Leukoencephalopathy will support a discussion of current challenges and future directions for PML treatment.

    Monday, June 24, 2013 | 10:30 AM - 3:00 PM

    Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine

    Speakers: Yasmine Belkaid (National Institute of Allergy and Infectious Diseases, NIH), Dan R. Littman (New York University School of Medicine), Alexander Rudensky (Memorial Sloan-Kettering Cancer Center)

    The Ross Prize, established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine, is awarded to an investigator producing innovative, paradigm-shifting research worthy of significant attention in molecular medicine.

    Tuesday, September 24, 2013 | 8:30 AM - 4:30 PM

    Harnessing New Players in Atherosclerosis to Treat Heart Disease

    Speakers: Karin Bornfeldt (University of Washington School of Medicine), Elena V. Galkina (Eastern Virginia Medical School), Emmanuel L. Gautier (Washington University School of Medicine, St. Louis), Klaus Ley (La Jolla Institute for Allergy and Immunology), Andrew H. Lichtman (Brigham and Women's Hospital, Harvard Medical School), Kathryn J. Moore (New York University Medical Center), Matthias Nahrendorf (Harvard Medical School), Alan R. Tall (Columbia University Medical Center)

    Currently available therapies fail to resolve the full burden of many cardiovascular diseases. Understanding the role of key hematopoietic and inflammatory players in this disease process may help identify new targets for fighting atherosclerosis.

    Friday, October 4, 2013 | 8:30 AM - 4:30 PM

    The Microbiome in Health, Disease, and Therapeutics: Bugs, Guts and Drugs

    Speakers: David Artis (University of Pennsylvania), Stephen M. Collins (McMaster University), Michael A. Fischbach (University of California, San Francisco), Dirk Gevers (The Broad Institute of MIT and Harvard), Jeremy K. Nicholson (Imperial College London), Lita M. Proctor (National Human Genome Research Institute, NIH)

    Symbioses between humans and our gut microbiome influence human biology including nutrition, immune function, and brain development. We review how symbiotic relationships impact drug metabolism and development, and a variety of disease states. This symposium features a poster session.

    Tuesday, October 22, 2013 | 8:30 AM - 4:30 PM

    Fibrosis: Therapeutic Target or Inevitable Outcome?

    Speakers: Yasmina Bauer (Actelion Pharmaceuticals Ltd), Jeremy S. Duffield (University of Washington), Raghu Kalluri (The University of Texas MD Anderson Cancer Center), Marco Prunotto (F. Hoffmann-La Roche), Richard M. Silver (Medical University of South Carolina), Dianqing (Dan) Wu (Yale University)

    Fibrosis is common in chronic organ injury, leading to progressive life-threatening outcomes. We review the link between fibrosis and disease and explore ways to use biomarkers and imaging to translate laboratory results into clinical success.

  • Past Events

    June 11 - 13, 2013

    Nanotechnologies in Cancer Diagnosis, Therapy, and Prevention

    Organizers: Mark E. Davis (California Institute of Technology, Pasadena), Omid Farokhzad (Brigham and Women's Hospital, Harvard Medical School), Brooke Grindlinger (The New York Academy of Sciences), Melanie Brickman Stynes (The New York Academy of Sciences), Roger Kornberg (Stanford University School of Medicine), Robert S. Langer (Massachusetts Institute of Technology), Konstantin Severinov (Rutgers the State University of New Jersey)

    Throughout the past decade nanoparticles, and specifically nanoparticle drug delivery systems, have emerged at the forefront of cancer therapies. This conference will discuss: nanodiagnostics for cancer biomarkers and imaging, toxicity and safety; nanovaccines and nanoimmunotherapeutics; targeted delivery in tumors; and nanoparticle-based gene therapy.

    Wednesday, June 5, 2013 | 12:00 PM - 4:00 PM

    Chemical Biology Discussion Group Year-End Symposium

    Keynote Speaker: Alanna Schepartz (Yale University)
    Speakers: Han Guo (Luo lab, Memorial Sloan–Kettering Cancer Center), Rudy Jacquet (Montclare lab, NYU-Poly), Neel Shah (Muir lab, Princeton University), Monika Raj (Arora lab, NYU), Wenjiao Song (Jaffrey lab, Weill Medical College, Cornell University), and Carola Wilczek (Shechter lab, Albert Einstein College of Medicine)

    The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs. The year-end meeting features keynote speaker Professor Alanna Schepartz of Yale University and a poster session.

    Monday, June 3, 2013 | 1:00 PM - 4:00 PM

    Genome Integrity Discussion Group Meeting

    Organizers: John Petrini (Memorial Sloan-Kettering Cancer Center), Rodney Rothstein (Columbia University Medical Center), Lorraine Symington (Columbia University Medical Center)
    Keynote Speaker: Stephen West (London Research Institute, Cancer Research UK)
    Speakers: Francisca Lottersberger (de Lange lab, Rockefeller University), Gerard Mazón (Symington lab, Columbia University Medical Center), Jiyong Wang (Jia lab, Columbia University), Christian Zierhut, PhD (Funabiki lab, Rockefeller University)

    The Genome Integrity Discussion Group provides a forum for interactions between basic and clinical research groups working on chromosome biology and function, and at the interface between chromosome integrity and onset and progression of malignancy.

    Thursday, May 30, 2013 | 9:00 AM - 5:00 PM

    Assessing the Plasmodium vivax Research Agenda: Interdisciplinary Workshops

    Review progress on key aspects of the Plasmodium vivax research agenda as they pertain to malaria treatment, control, and elimination through a series of free, interdisciplinary workshops.

  • Publications 

    Annals

    Annals Meeting Reports

    Edited by Annals of the New York Academy of Sciences editorial staff

    A collection of four meeting reports on omics platforms in diabesity, prioritizing health disparities in medical education, the paradox of overnutrition, and vitamin D: beyond bone.

    Annals

    The Renaissance of Cancer Immunotherapy: The 7th International Cancer Vaccine Symposium

    Edited by Olivera J. Finn (University of Pittsburgh, Pittsburgh, Pennsylvania) and Gerold Schuler (University Hospital of Erlangen, Erlangen, Germany)

    This Annals volume presents papers that discuss progress of immunology research toward the development of cancer vaccines.

    eBriefing

    Treatment-resistant Depression: Glutamate, Stress Hormones, and their Role in the Regeneration of Neurons

    Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), and Jennifer Henry (The New York Academy of Sciences)
    Speakers: Ronald S. Duman (Yale University School of Medicine), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone B. Sartori (University of Innsbruck, Austria), and Carlos A. Zarate (National Institute of Mental Health, NIH)

    Major depression is a devastating illness; current therapies based on monoamine neurotransmitters are beneficial for only one in ten patients. This eBriefing reviews a paradigm shift in treatment that targets the glutamatergic neurotransmitter system.

    eBriefing

    Current Dietary Phosphorus Intake: Are there Potential Implications for Public Health?

    Organizers: Jaime Uribarri (The Mount Sinai School of Medicine), Mona S. Calvo (U.S. Food and Drug Administration), and Mandana Arabi (The Sackler Institute for Nutrition Science)

    The availability of dietary phosphorus has increased because of its widespread use as an additive in processed foods. Explore whether hyperphosphatemia has health implications at the population level.

  • Podcasts

    Podcast
    September 10, 2010

    What Makes Us Wise?

    Can we all be wise old owls? Science journalist Stephen Hall and neuroscientist Andre Fenton dissect what we call wisdom, from the neurons in our brain, to the social constructs behind it.

    Download (22 MB, 00:42:32)
    Podcast
    July 30, 2010

    Oxidative Stress

    Foods high in antioxidants are believed to fight oxidative stress. But what is oxidative stress? Two scientists from a recent NYAS conference break it down and discuss whether antioxidants have superpowers.

    Download (12 MB, 00:18:37)
    Podcast
    July 2, 2010

    What's that Smell?

    Biologist Stewart Firestein and world-renowned perfumer Christophe Laudamiel team up to tackle the science of smell.

    Download (32 MB, 00:49:12)
    Podcast
    April 2, 2010

    More than a Yogurt Cup

    Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.

    Download (14 MB, 00:21:21)
  • Webinar Archives

    Webinar Archive
    February 23, 2010

    Metabotropic Glutamate Receptors: Translation from Discovery to Clinical Trials

    Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.

    Webinar Archive
    October 27, 2009

    Is Alzheimer's Disease Type 3 Diabetes?

    What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.

    Webinar Archive
    April 28, 2009

    Protein Kinases: Structure-Guided Drug Discovery

    Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.

  • Translational Medicine Initiative

    Macy FoundationThe Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.

    Learn more at www.nyas.org/TransMed.